BioVaxys Technology Corp.
Vancouver, Bc (ots/PRNewswire)
BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF) (“BioVaxys” or the “Company”) is pleased to announce that Dasha Enenko has been appointed as the Company’s Chief Financial Officer (“CFO”) A Chartered Professional Accountant, she has over 12 years of accounting experience for private, public and not-for-profit companies in a variety of industries including e-commerce, technology, manufacturing, food and beverage and real estate Preparing and preparing interim and annual financial statements for public companies, working with auditors to ensure successful completion of audit and audit engagements, and assisting clients in preparing prospectuses Dasha is CFO of Nextgen Food Robotics Corp.
Craig Loverock, BioVaxys’ outgoing CFO, has been appointed to the Board of Directors of BioVaxys. As finance professional, Craig will chair the audit committee and other relevant committees of the board. BioVaxys thanks Craig for his excellent work as CFO during his tenure. CraigCraig fills the vacancy created by David Wang’s resignation from the company’s board of directors. David is returning to his residence in China and will not be able to find sufficient time to serve as a director of the company. David has been appointed as an advisor to BioVaxys to support the company’s business development in China, including identifying potential licensing, divestment, merger and acquisition opportunities with Chinese pharmaceutical companies.
James Passin, CEO of BioVaxys stated, “We are pleased to bring Dasha Enenko on board as CFO as we continue to work to further develop our product portfolio. We thank Craig for his excellent work as CFO during his tenure and welcome him to the Board. We look forward to continuing to work with former director David Wang on opportunities in China.”
About BioVaxys Technology Corp.
BioVaxys Technology Corp. ( www.biovaxys.com) based in Vancouver is a clinical-stage biotechnology company registered in British Columbia developing viral and oncology vaccine platforms and immunodiagnostics. The Company is developing vaccines against SARS-CoV-2, SARS-CoV-1 and a pan-Sarbecovirus vaccine based on its haptenized viral protein technology and is planning a clinical trial of its haptenized autologous cell vaccine combined with anti-PD1 and anti-PDL1 checkpoint inhibitors to be initially developed for stage III/stage IV ovarian cancer. Also in development is CoviDTH®, a diagnostic to assess the presence or absence of a T cell immune response to SARS-CoV-2, the virus that causes COVID-19. BioVaxys has two issued US patents and multiple US and international patent applications related to its cancer vaccines, antiviral vaccines and diagnostic technologies. BioVaxys common stock is listed on the CSE under the ticker symbol “BIOV” and trades on the Frankfurt Stock Exchange (FRA: 5LB) and the United States (OTCQB: BVAXF).
ON BEHALF OF THE BOARD OF DIRECTORS
Drawn James Passin
James Passin, CEO
+1 646 452 7054
Cautionary Statements Regarding Forward-Looking Statements
This press release contains certain “forward-looking information” and “forward-looking statements” (collectively, “forward-looking statements”) within the meaning of applicable Canadian and U.S. securities laws, including the United States Private Securities Litigation Reform Act of 1995. All statements contained herein, except Statements of historical fact, without limitation, relating to the Company’s future operating or financial performance are forward-looking statements. Forward-looking statements are often, but not always, qualified by words such as “expects,” “anticipates,” “believes,” “intends”, “estimates”, “potential”, “possible” and similar expressions, or statements that events, conditions or results “will”, “may”, “could” or “should” occur or be achieved. Forward-looking statements in this press release relate to, among other things, the completion of the animal model study, regulatory approval for a Phase I human trial of vaccine candidate BVX-1021, and the overall development of BioVaxys’ vaccines, including a haptenized SARS-Cov-2 or SARS-CoV protein vaccine. There can be no assurance that such statements will prove to be accurate, and actual results and future events could differ materially from those expressed or implied by such forward-looking statements.
These forward-looking statements reflect the beliefs, opinions and projections as of the date the statements are made and are based on a number of assumptions and estimates, primarily the assumption that BioVaxys will be successful in developing and testing vaccines. While these assumptions and estimates are believed to be reasonable by the Company, they are inherently subject to significant business, economic, competitive, political and social uncertainties and contingencies, including without limitation the risk that BioVaxys’ vaccines will not prove effective and/or failed to obtain the necessary regulatory approvals. There are a number of risks related to BioVaxys’ business that could affect the development of its biotechnology products. These include, but are not limited to, the need for additional capital to fund clinical trials, the Company’s lack of operational experience, uncertainty as to whether its products will pass the long, complex and expensive process of clinical trials and regulatory approval of new drugs required for market approval. undergo, the uncertainty as to whether its autologous cell vaccine immunotherapy can be developed to produce safe and effective products and, if so, whether its vaccine products will be commercially accepted and viable, the expenses, delays, uncertainties and complications typically encountered by biopharmaceutical companies in the development phase, financial and developmental obligations under licensing agreements to protect their rights to their products and technologies, obtaining and protecting new intellectual property rights and avoiding infringement by third parties, and their dependence on third-party manufacturing.
The Company undertakes no obligation to update any forward-looking statements about beliefs, opinions, projections or other factors should they change, except as required by law.
QUELLE: BioVaxys Technology Corp.
Logo – https://mma.prnewswire.com/media/1430981/3815872/BIOVAXYS_Logo.jpg
Original content from: BioVaxys Technology Corp., transmitted by news aktuell